Neurontin’s Effectiveness Apparently Overstated by Pfizer

“There is good evidence of selective outcome reporting in published reports of randomized trials.” So begins the abstract of a special report in the Nov. 12 New England Journal of Medicine. In the report, clinical trial and health policy experts examine original company documents and journal articles related to non-U.S. Food and Drug Administration-approved uses…

read more

Misleading Prescription Drug Advertisements, like Fentanyl/Duragesic Patches, Lead to Major Injuries and Death

Johnson & Johnson (J&J), one major manufacturer of Fentanyl and Duragesic pain patches, made bold proclamations regarding the effectiveness and ease in which you can take these prescription patches, but they failed to mention the high risk of accidental overdose deaths. The most well-known J&J advertisements boasted, “Duragesic stops the pain, not the patient” and “Life…

read more

FDA Not Ordering Untested, Unsafe Drugs Off U.S. Market, Review Finds

For the second time in the three years, independent federal investigators have determined that the U.S. Food and Drug Administration has failed to require the timely delivery of safety and efficacy data on medications the agency approved before pharmaceutical manufacturers have completed clinical trials. The FDA has also declined to take actions to remove medications…

read more